[Pre-Aug 2018] IMSCAR

  1. Cyhoeddwyd

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Maw 2010, Yn : Clinical Pharmacology and Therapeutics. 87, 3, t. 257-261

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygl

  2. Cyhoeddwyd

    A Framework for Planning and Critiquing Medication Compliance and Persistence Research Using Prospective Study Designs.

    Hughes, D., Gwadry-Sridhar, F. H., Manias, E., Zhang, Y., Roy, A., Yu-Isenberg, K., Hughes, D. A. & Nichol, M. B., 1 Chwef 2009, Yn : Clinical Therapeutics. 31, 2, t. 421-435

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygl

  3. Cyhoeddwyd

    The cost-effectiveness of biological therapies for Crohn's disease: Markov cohort analyses incorporating UK patient-level cost data.

    Hughes, D., Bodger, K., Kikuchi, T. & Hughes, D. A., 1 Ion 2008.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  4. Cyhoeddwyd

    Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease

    Hughes, D. & Hughes, D. A., 1 Tach 2004, Yn : Value in Health. 7, 6, t. 753

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygl

  5. Cyhoeddwyd

    Physchiatrist prescribing preferences and attitudes toward promotion

    Hughes, D., Menkes, D., Davies, R. & Hughes, D. A., 1 Ebr 2006.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  6. Cyhoeddwyd

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Gorff 2007.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  7. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Epoetin delta (Dynepo)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  8. Cyhoeddwyd

    The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies.

    Hughes, D. & Hughes, D. A., 1 Ion 2001, 2001 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  9. Cyhoeddwyd
  10. Cyhoeddwyd

    Methodological issues in the literature on costs of non-compliance in chronic diseases.

    Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeier, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Ion 2008.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  11. Cyhoeddwyd

    Defining rewardable innovation in drug therapy

    Hughes, D., Aronson, J. K., Ferner, R. E. & Hughes, D. A., 1 Ebr 2012, Yn : Nature Reviews Drug Discovery. 11, t. 253-254

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygl

  12. Cyhoeddwyd

    What determines which interventions improve compliance, and do they improve health outcomes in a cost-effective manner?

    Hughes, D., Hughes, D. A., LaFleur.*, N. V., Salas, M. & Shinogle, J., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  13. Cyhoeddwyd

    Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

    Hughes, D. & Hughes, D. A., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  14. Cyhoeddwyd

    From efficacy to effectiveness and cost-effectiveness: modelling possibilities

    Hughes, D. & Hughes, D. A., 1 Tach 2004.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  15. Cyhoeddwyd

    Abolition of prescription copayments in Wales: an observational study on dispensing rates.

    Hughes, D., Cohen, D., Alam, M. F., Dunstan, F. D., Myles, S., Hughes, D. A. & Routledge, P. A., 1 Awst 2010, Yn : Value in Health. 13, 5, t. 675-680

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygl

  16. Cyhoeddwyd

    Decision-Makers’ Preferences for Approving New Medicines in Wales: A Discrete-Choice Experiment with Assessment of External Validity

    Hughes, D., Linley, W. G. & Hughes, D. A., 1 Ebr 2013, Yn : Pharmacoeconomics. 31, 4, t. 345-355

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygl

  17. Cyhoeddwyd
  18. Cyhoeddwyd

    HLA-B*5701 and abacavir hypersensitivity - Reply.

    Hughes, D., Hughes, D. A., Park, B. K. & Pirmohamed, M., 1 Tach 2004, Yn : Pharmacogenetics. 14, 11, t. 784

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygl

  19. Cyhoeddwyd

    Estimating Drug Costs in Economic Evaluations in Ireland and the UK: An Analysis of Practice and Research Recommendations.

    Hughes, D., Hughes, D. A., Tilson, L. & Drummond, M. F., 1 Mai 2009, Yn : Pharmacoeconomics. 27, 8, t. 635-643

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygl

  20. Cyhoeddwyd

    Less is more: Medicines that require less frequent administration improve adherence, but are they better?

    Hughes, D. & Hughes, D. A., 1 Ion 2006, Yn : Pharmacoeconomics. 24, 3, t. 211-213

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygl

  21. Cyhoeddwyd

    Economic evaluation of a behavior-modifying intervention to enhance antiepileptic drug adherence

    Hughes, D., Plumpton, C. O., Brown, I., Reuber, M., Marson, A. G. & Hughes, D. A., 26 Maw 2015, Yn : Epilepsy and Behavior. 45, t. 180-186

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygl

  22. Cyhoeddwyd

    Health and economic outcomes: Why compliance matters

    Hughes, D. & Hughes, D. A., 1 Ebr 2006.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  23. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Ziconotide (Prialt) for the intrathecal treatment of severe, chronic pain.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  24. Cyhoeddwyd

    A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)

    Hughes, D., Ramanan, A., Dick, A. D., Benton, D., Compeyrot-Lacassagne, S., Dawoud, D., Hardwick, B., Hickey, H., Hughes, D. A., Jones, A., Woo, P., Edelsten, C., Beresford, M. W. & The SYCAMORE Trail Management Group, N. V., 9 Ion 2014, Yn : Trials. 15, 14

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygl

  25. Cyhoeddwyd

    Identification and Assessment of Adherence-Enhancing Interventions in Studies Assessing Medication Adherence Through Electronically Compiled Drug Dosing Histories: A Systematic Literature Review and Meta-Analysis

    Hughes, D., Holmes, E. A., Demonceau, J., Ruppar, T., Kristano, P., Hughes, A. D., Fargher, E., Przemyslaw, K., De Geest, S., Dobbels, F., Lewek, P., Urquhart, J. & Vrijens, B., 1 Mai 2013, Yn : Drugs. 73, 6, t. 545-562

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygl

  26. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  27. Cyhoeddwyd

    Drugs for exceptionally rare diseases: do they deserve special status for funding?

    Hughes, D., Tunnage, B. & Yeo, S. T., 1 Tach 2005, Yn : QJM - An International Journal of Medicine. 98, 11, t. 829-836

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygl

  28. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  29. Cyhoeddwyd

    Pharmacoeconomic models that incorporate non-compliance

    Hughes, D. & Hughes, D. A., 1 Gorff 2004.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  30. Cyhoeddwyd

    Estimation of the impact of noncompliance on pharmacokinetics: an analysis of the influence of dosing regimens

    Hughes, D. & Hughes, D. A., 1 Rhag 2008, Yn : British Journal of Clinical Pharmacology. 65, 6, t. 871-878

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygl

  31. Cyhoeddwyd
  32. Cyhoeddwyd

    Follow-up of cancer patients in primary care versus secondary care: systematic review.

    Hughes, D., Lewis, R., Neal, R., Williams, N., France, B., Wilkinson, C., Hendry, M., Russell, D., Hughes, D. A., Russell, I. T., Stuart, N. S. & Weller, D., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  33. Cyhoeddwyd

    From efficacy to cost-effectiveness: accounting for non-compliance in pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 Mai 2002.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  34. Cyhoeddwyd

    The pharmacokinetic profile of Warfarn: a systematic review

    Hughes, D., Al-Zubiedi S.*, N. V., Hughes D.A., N. V. & Pirmohamed, M., 1 Rhag 2007.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  35. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  36. Cyhoeddwyd

    Economic evaluation during early (phase II) trials

    Hughes, D. & Hughes, D. A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  37. Cyhoeddwyd

    Costs of Medication Nonadherence in Patients with Diabetes Mellitus: A Systematic Review and Critical Analysis of the Literature.

    Hughes, D., Salas, M., Hughes, D. A., Zuluaga, A., Vardeva, K. & Lebmeier, M., 1 Medi 2009, Yn : Value in Health. 12, 6, t. 915-922

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygl

  38. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Docetaxel (Taxotere) for locally advanced squamous cell carcinoma of the head and neck.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  39. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  40. Cyhoeddwyd

    Accounting for non-compliance in pharmacoeconomic evaluations.

    Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Ion 2001, Yn : Pharmacoeconomics. 19, 12, t. 1185-1197

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygl

  41. Cyhoeddwyd

    The Population Pharmacokinetics of R and S-Warfarin: Effect of Genetic and Clinical Factors

    Hughes, D., Lane, S., Al-Zubiedi, S., Hatch, E., Matthews, I., Jorgensen, A. L., Deloukas, P., Daly, A. K., Aarons, L., Ogungbenro, K., Kamali, F., Hughes, D. A. & Pirmohamed, M., 1 Ion 2012, Yn : British Journal of Clinical Pharmacology. 73, 1, t. 66-76

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygl

  42. Cyhoeddwyd

    Accurate and practical dosing of African populations using a height, weight and age model designed for lapdap

    Hughes, D., Hughes, D. A. & Bagust, A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  43. Cyhoeddwyd

    Public health interventions to promote mental well-being in people aged 65 and over: systematic review of effectiveness and cost-effectiveness.

    Hughes, D., Windle, G., Hughes, D. A., Linck, P., Morgan, R., Burholt, V., Edwards, R. T., Reeves, C., Yeo, S. T., Woods, R. T. & Russell, I. T., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  44. Cyhoeddwyd

    Investigating factors influencing user choices to visit either general practioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment.

    Hughes, D., Hughes, D. A., Myles, S., Longo, M. & Lisles, C., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  45. Cyhoeddwyd

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  46. Cyhoeddwyd

    Systematic review of follow-up of cancer in primary care verses secondary care: findings for breast and lung cancer

    Hughes, D., Lewis, R., Neal, R. D., France, B., Williams, N. H., Wilkinson, C., Russell, I. T., Russell, D., Hughes, D. A., Stuart, N. S. & Weller, D., 1 Maw 2007.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  47. Cyhoeddwyd

    A single centre open phase IV study to evaluate the safety and tolerability of chlorproguanil-dapsone when dosed by defined height bands

    Hughes, D., Makanga, M., Winstanley, P. & Hughes, D. A., 1 Tach 2004.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  48. Cyhoeddwyd

    Mechanism-Based Approach to the Economic Evaluation of Pharmaceuticals: Pharmacokinetic/Pharmacodynamic/Pharmacoeconomic Analysis of Rituximab for Follicular Lymphoma.

    Hughes, D., Pink, J., Lane, S. & Hughes, D. A., 19 Maw 2012, Yn : Pharmacoeconomics.

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygl

  49. Cyhoeddwyd

    Chiral chromatography: Costs of chiral switching.

    Hughes, D. & Hughes, D. A., 1 Ion 2008, Yn : Pharmaceutical Journal. 281, t. 213

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygl

  50. Cyhoeddwyd

    Use of PK-PD modelling to predict the impact of non-compliance

    Hughes, D. & Hughes, D. A., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur